Silibinin combined with neratinib or etoposide significantly promotes apoptosis in breast cancer (4T1, MCF-7, and MDA-MB-231) cells by up-regulating the protein expression of p53 and p21 [932, 933]. This evidence concerns the gene CDKN1A and breast carcinoma.